Efficiency of erenumab in neurologist’s real practice

Close metadata

OBJECTIVE

To assess the effectiveness and safety of erenumab in real-life study.

MATERIAL AND METHODS

33 patients with episodic and chronic migraine (30 females, mean age 39.2±9.2, 3 males, mean age — 49.3±7.6) received erenumab 70 mg for each 3 months. Patients achieved a 50% reduction in the number of days with headache, pain intensity, duration, the number of days of acute medication use, effect on daily activity (HIT-6), side effects, neuropsychological testing (Beck Depression scale, Spielberger-Khanin questionnaire, Hospital Depression and Anxiety Scale) were assessed.

RESULTS

During the first month of therapy, a 50% decrease in headache days was observed in 48% of patients, during the second — in 53% of patients, during the third — in 51.5% of patients (p<0.001), a reduce in pain intensity, HIT-6 score, duration of migraine attack was observed (p<0.005). A decrease in situational anxiety was revealed (Spielberger—Khanin questionnaire, p=0.02), but not depression. There was a decrease in the consumption of triptans (p<0.0005) and other analgesics (p=0.0018). 1 patient noted transient constipation.

CONCLUSION

The effectiveness and safety of erenumab in the outpatient practice is shown.

Keywords:

migraine

migraine without aura

migraine with aura

episodic

chronic migraine

biological therapy of migraine

erenumab

Authors:

Belskaya G.N.

Research Center of Neurology

Kiryanova E.A.

Research Center of Neurology

Krasnikov A.V.

Research Center of Neurology

Prokopovich M.E.

Research Center of Neurology

Sakharova E.V.

Research Center of Neurology

Received:

31.05.2022

Accepted:

02.06.2022

List of references:

ICHD-3. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211. https://doi.org/10.1177/0333102417738202
Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38:182-190. https://doi.org/10.1055/s-0038-1646946
Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954-976. https://doi.org/10.1016/S1474-4422(18)30322-3
Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32:373-381. https://doi.org/10.1177/0333102412438977
Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(17):1-4. https://doi.org/10.1186/s10194-018-0846-2
Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments. CNS Drugs. 2012;26(5):375-382. https://doi.org/10.2165/11630590-000000000-00000
Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470-485. https://doi.org/10.1177/0333102416678382
Schoenen J, Manise M, Nonis R, et al. Monoclonal antibodies blocking CGRP transmission: An update on added value in migraine prevention. Rev Neurol. 2020;176(10):788-803. https://doi.org/10.1016/j.neurol.2020.04.027
Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6-12. https://doi.org/10.1186/s10194-018-0955-y
Ashina M, Kudrow D, Reuter U, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798-1808. https://doi.org/10.1177/0333102419888222
Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year openlabel extension study in episodic migraine. Cephalalgia. 2019;39(11):1455-1464. https://doi.org/10.1177/0333102419854082
Brandes JL, Diener HC, Dolezil D, et al. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving 50%, 75%, and 100% response. Cephalalgia. 2020;40(1):28-38. https://doi.org/10.1177/0333102419894559
Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-2287. https://doi.org/10.1016/S0140-6736(18)32534-0
Russo A, Silvestro M, di Clemente FS, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):1-14. https://doi.org/10.1186/s10194-020-01143-0
Xu D, Chen D, Zhu LN, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine — a meta-analysis of randomized controlled trials. Cephalalgia. 2019;39:1164-1179. https://doi.org/10.1177/0333102419829007
Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020;94(5):497-510. https://doi.org/10.1212/WNL.0000000000008743
Tabeeva GR, Osipova VV, Filatova EG, et al. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):4-13. (In Russ.). https://doi.org/10.14412/2074-2711-2022-1-4-13
Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4-14. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-4-14
Artemenko AR, Plieva AM, Shmidt DA, et al. Monoclonal antibobody erenumab for migraine prevention: a review of new data. Russian Neurological Journal. 2021;26(2):11-16. (In Russ.). https://doi.org/10.30629/2658-7947-2021-26-2-11-16
Vashchenko NV, Korobkova DZ, Skorobogatykh KV, Azimova YuE. Efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice: preliminary analysis after three months of therapy. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):62-66. (In Russ.). https://doi.org/10.14412/2074-2711-2021-6-62-66
Dobrynina LA, Gubanova MV, Belopasova AV, et al. The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(2):74-80. (In Russ.). https://doi.org/10.17116/jnevro202212202174
Berdnikova AV, Kadymova NV, Latysheva NV, et al. Real-world efficacy and safety of Erenumab: a prospective study of 80 patients in a specialized headache center. Russian Neurological Journal. 2022;27(1):43-50. (In Russ.). https://doi.org/10.30629/2658-7947-2022-27-1-43-50
Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):1-11. https://doi.org/10.1186/s10194-020-01102-9
Barbanti P, Aurilia C, Cevoli S, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache J Head Face Pain. 2021;61(9):1351-1363. https://doi.org/10.1111/head.14194
Tepper S, Broessner G, Buse D, et al. Efficacy of Erenumab for the Treatment of Patients with Episodic Migraine with Depression and/or Anxiety. Neurology. 2018;90(15):suppl 4.105. Online ISSN: 1526-632X
Schoenen J, Timmermans G, Nonis, et al. Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability and differences between clinical phenotypes. Front Neurol. 2021;12:805334.

Close metadata